J&J's (JNJ) Tremfya Meets Goal In Psoriatic Arthritis Study
Zacks Investment Research | Jun 17, 2019 05:26AM ET
Johnson & Johnson’s (NYSE:JNJ) subsidiary Janssen announced top-line results from the phase III DISCOVER 1 and 2 studies on its IL-23 inhibitor, Tremfya/guselkumab. Both studies evaluated the safety and efficacy of Tremfya as compared to placebo for treating adult patients with active moderate to severe psoriatic arthritis (PsA).
The studies met the primary endpoint of American College of Rheumatology 20% improvement while the safety profile was consistent with the previous programs on Tremfya/guselkumab.
Tremfya was first approved in the United States and the EU in 2017 for the treatment of moderate-to-severe plaque psoriasis.
Based on data from the two DISCOVER studies, Janssen will submit a regulatory filing to the FDA and the European Medicines Agency (EMA) for an approval to expand the label of Tremfya as a treatment for psoriatic arthritis, later this year.
The company plans to present data from the DISCOVER program at an upcoming medical conference.
The double-blind, phase III DISCOVER-1 and DISCOVER-2 studies evaluated the safety and the efficacy of Tremfya (subcutaneous) in patients with active PsA as compared to the placebo arm. Apart from the primary endpoint, the program also assessed several secondary endpoints. The DISCOVER-2 probe analyzed the effect on structural damage (vdH-S) as a key secondary endpoint.
Shares of J&J have increased 8.5% so far this year, outperforming the industry’s rise of 2.1%.
Notably, Tremfya is off to a promising start following its launch in 2017 and has contributed significantly to the company’s growth ever since. The drug recorded sales of $217 million in the first quarter of 2019 compared with $175 million in fourth-quarter 2018.
Meanwhile, Tremfya proved its superiority over the other drugs in the past. Last December, J&J announced results from a head-to-head phase III ECLIPSE evaluation, which compared Tremfya with Novartis' (NYSE:NVS) psoriasis drug, Cosentyx (secukinumab).
The outcomes showed that after a 48-week treatment, 84.5% of the patients treated with Tremfya achieved 90% improvement in disease symptoms as measured by the Psoriasis Area Severity Index in comparison to 70% with respect to Novartis's Cosentyx.
The drug is also being studied for various other indications as well. A phase IIb study is evaluating Tremfya for the treatment of Crohn’s disease. Two other phase II studies are investigating the drug for ulcerative colitis and hidradenitis suppurativa.
Get The News You Want
Zacks Rank & Stocks to Consider
J&J currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the large cap pharma sector include AbbVie Inc. (NYSE:ABBV) and Merck & Co., Inc. (NYSE:MRK) , both sporting a Zacks Rank #2 (Buy). You can see .
AbbVie’ earnings estimates have been revised 1.5% upward for 2018 and 1.4% for 2019 over the past 60 days.
Merck’s earnings estimates have moved 1.7% north for 2019 and 0.6% for 2020 over the past 60 days. The stock has rallied 8.1% year to date.
Radical New Technology Creates $12.3 Trillion Opportunity
Imagine buying Microsoft (NASDAQ:MSFT) stock in the early days of personal computers… or Motorola (NYSE:MSI) after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors.
Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” - and early investors stand to earn the biggest profits.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.